Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331:143 (16 July), doi:10.1136/bmj.38496.452581.8F (published 22 June 2005)
Dee Richards, senior lecturer1, Les Toop, professor1, Stephen Chambers, professor2, Lynn Fletcher, biostatistician1
1 Department of Public Health and General Practice, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand, 2 Department of Pathology, Christchurch School of Medicine and Health Sciences
Correspondence to: D Richards derelie.richards{at}chmeds.ac.nz
Design Prospective, double blind, randomised, placebo controlled trial.
Setting Primary care, among a randomly selected group of general practitioners in Christchurch, New Zealand.
Participants 59 women aged 16-50 years presenting with a history of dysuria and frequency in whom a dipstick test of midstream urine was negative for both nitrites and leucocytes. Participants with complicated urinary tract infection were excluded.
Intervention Trimethoprim 300 mg daily for three days or placebo.
Main outcome measures Self reported diary of symptoms for seven days, recording the presence or absence of individual symptoms each day, followed by a structured telephone questionnaire after seven days. The main clinical outcome was resolution of dysuria at three and seven days and median time to resolution. Secondary outcomes were resolution of other symptoms.
Results The median time for resolution of dysuria was three days for trimethoprim compared with five days for placebo (P = 0.002). At day 3, five (24%) of patients in the treatment group had ongoing dysuria compared with 20 (74%) in the placebo group (P = 0.005). This difference persisted until day 7: two patients (10%) in the treatment group v 11 (41%) in the placebo group; P = 0.02). The number needed to treat was 4. The median duration of constitutional symptoms (feverishness, shivers) was reduced by four days.
Conclusions Although a negative dipstick test for leucocytes and nitrites accurately predicted absence of infection when standard microbiological definitions were used (negative predictive value 92%), it did not predict response to antibiotic treatment. Three days' treatment with trimethoprim significantly reduced dysuria in women whose urine dipstick test was negative. These results support the practice of empirical antibiotic use guided by symptoms. Balancing the competing interests of symptom relief and the minimisation of antibiotic use remains a dilemmafurther research is needed to determine clinical predictors of response to antibiotics.
Of 374 specimens collected, 96 (26%) were negative for both leucocytes and nitrites.5 Eight of these (8%) contained pure growth cultures above the standard conservative cut-off point of 100x106 colony forming units per litre.6 The negative predictive value of the dipstick test was 92%.
The approach to women with symptoms of uncomplicated urinary tract infection and positive urine dipstick results is to give empirical antibiotic treatment.7-9 Recommendations for the treatment of women with symptoms and negative dipstick results vary. Some suggest empirical treatment,1 10 but others do not.7 8 11 We carried out a pragmatic trial of antibiotic compared with placebo in women with symptoms of uncomplicated urinary tract infection and negative dipstick results.
Participants
We invited women to participate who were aged between 16 and 50 and presenting with a history of dysuria and frequency to general practitioners from the randomly selected Christchurch sentinel network.5 Seventy five (91%) of the original 82 randomly selected general practitioners in the network were participating in a surveillance study, and 30 (40%) of these agreed to recruit patients for the randomised controlled trial. Exclusion criteria were a dipstick test that was positive for leucocytes or nitrites, complicated urinary tract infections, pregnancy, or known allergy to trimethoprim. We also excluded women with proved urinary tract infection or treatment for presumed urinary tract infection in the past month.
All the women who agreed to participate provided a midstream urine specimen that their general practitioner tested immediately with a standard urine dipstick and then sent for microbiological examination and culture. We randomly allocated patients whose dipstick test was negative for both leucocytes and nitrites to receive either three days of trimethoprim 300 mg (standard treatment) or placebo. To randomise the participants, the biostatistician chose SAS code, which used random block lengths with a maximum of 10 to generate a random sequence for the medication packs. This went to a dispensing pharmacist, together with a sequential alphanumerical code list. The pharmacist prepared identical placebo and active drug capsules and attached an alphanumerical code to the medication bottles that the patients received from their general practitioner. The pharmacist put the codes with the list identifying allocation to placebo or treatment in a sealed envelope. The study team and general practitioners enrolling patients had no access to the code list until the data collection was complete. Labels preprinted with the code were provided to attach to the patient's clinical notes as well as the initial urinary specimen form and questionnaire. General practitioners, investigators, and research nurses were all blind to allocation until the data collection was complete.
105 organisms/ml of urine. Participants completed a short written questionnaire at the surgery. This asked about demographic details, current symptoms, including, on the day the participant entered the trial, the presence or absence of dysuria, increased urinary frequency, low back pain, abdominal pain, appearance of blood in the urine, itching, and feeling "hot or shivery." Women were also asked about potential risk factors for infection, including use and type of contraceptive, recent sexual activity, past history of infection, and use of other preparations to alleviate symptoms. Participants received a seven day diary to record their symptoms and return by mail. They recorded the presence or absence of individual symptoms each day. We contacted all women after seven days and administered a structured telephone questionnaire, recording the presence or absence of each symptom. Where a symptom was absent and had been recorded as present on the day 1 questionnaire, we asked the woman to recall the day on which the symptom resolved. Adverse effects potentially related to medication and any other treatments taken were recorded. We asked participants to provide a second midstream urine specimen for microbiological examination and culture.
The main outcome was resolution of dysuria in the intervention and control groups at three and seven days, and median time to resolution. Secondary outcomes were resolution of other symptoms. We investigated predictors of response to treatment.
2 = 0.05, the study has 78% power to show a difference between groups if the "true" rates are such that symptoms will not resolve in only 10% of women taking antibiotics compared with 40% of women taking placebo. This sample size has 99% power to detect a difference between groups if the true rates are such that symptoms will not resolve in only 25% of women taking antibiotics compared with 75% of women taking placebo.
We used the median test to analyse days to resolution by symptom, and, where appropriate, we also calculated the number needed to treat. We included women whose symptoms had not resolved in this analysis, with censoring after day 7. We used the
2 test for contingency tables to analyse proportions. We used SAS, version 8.02 (SAS Institute, Cary, North Carolina, USA), to carry out all our analyses.
|
|
|
|
No patient or illness characteristic predicted response to treatment at day 3. Twenty six participants had
20 leucocytes per ml in their urine on microscopy, 13 in each arm, and this did not predict response to treatment. In the placebo arm, 6/13 (46%) of those who reported no dysuria at day 3 and 7/20 (35%) who still reported dysuria had pyuria at trial entry. In the treatment arm, 8/19 (42%) of those who reported no dysuria at day three and 5/7 (71%) who still reported dysuria had pyuria at trial entry. Five women had microbiological evidence of bacterial infection on midstream urine testing when we used standard criteria of
20 leucocytes/ml of urine and pure growth of
105 organisms/ml of a uropathogen.6 Four of these grew Escherichia coli and one Klebsiella pneumoniae. Three were in the treatment arm and two in the placebo arm. The negative predictive value of the dipstick in this study was therefore 92%. Six women had low count bacteriuria, three in each arm, and this did not predict response to treatment.
We obtained follow-up urine specimens from 42 participants (71%). Two participants had clinically significant bacteriuria (E coli in both cases), both of whom were in the placebo arm, and 13 had
20 leucocytes/ml in their urine on microscopy.
We saw few adverse effects in either arm. Six patients (18%) in the placebo arm and three (12%) in the treatment arm reported minor symptoms (nausea, sore mouth, itching skin, sedation after taking medication, mouth ulceration, and thrush). Nine patients in each group (treatment group 29%, placebo group 35%) had used other preparations. These included cranberry juice, urinary alkalinisers, herbal preparations, and homeopathic remedies.
Strengths and limitations of the study
The pragmatic design of this trial is its strength. Trials of antibiotics are usually limited to patients who have been screened for microbiologically confirmed infection, with the assumption that patients who do not show infection will not respond to treatment. In general practice treatment for uncomplicated urinary tract infection is usually empirical and not informed by individual microbiological results. Response to treatment is also an important indicator of clinical outcome, given that symptom relief, not microbiological cure, is the main aim of treatment. The negative predictive value of 92% for the dipstick test in this study was consistent with international studies and implies that the results are generalisable to other primary care populations.3
2
The study had some limitations. The unexpectedly high positive response to antibiotics reduced the power to assess predictors of response to treatment, as there were so few non-responders. Generalisability must be considered in the light of the fact that not all potentially eligible women were recruited for the study. Other organisms have been implicated in dysuria and frequency. We did not test for Chlamydia trachomatis. However, C trachomatis does not respond to trimethoprim and if cases were inadvertently included they would not have accounted for the observed effect of trimethoprim.
A proportion of these patients may have had low count bacteriuria with conventional pathogens reflecting cystitis, urethritis, or "female prostatitis" and might be expected to respond to trimethoprim.4 6 13-16 It is of interest that Stamm also identified a separate group of patients without pyuria who had an acute dysuria syndrome very similar to those with low count bacteriuria but for which no organism could be found.4 To our knowledge this group has not been investigated further to assess the effectiveness of treatment.
Implications for clinical practice
If the results of this study with trimethoprim are confirmed in similar studies the use of urine dipstick testing and standard midstream urine culture and microscopy to inform prescribing decisions in women with symptoms of uncomplicated urinary tract infection should be reviewed. These results show that empirical treatment with antibiotics of (dipstick positive and dipstick negative) patients presenting in primary care is justified irrespective of dipstick findings. The downside of such a strategy is an increase in adverse events, superinfection, and increased antibiotic pressure with the consequent promotion of bacterial resistance. Such a policy would further highlight the tension between relieving symptoms expeditiously with the desire to minimise unnecessary antibiotic use.17 More discriminating ways to avoid unnecessary antibiotic exposure are needed.
Conclusions
Although negative dipstick results are useful in predicting which women aged 16-50 presenting with symptoms of urinary tract infection will have a negative urine culture, these results show that it does not follow that this will predict response to antibiotic treatment. Further clinical and microbiological study of the group of women who seem not to have infection yet whose symptoms are relieved more quickly with a short course of trimethoprim is needed to understand the aetiology of symptoms in this group. At a population level, a need also exists to find a more discriminating way to avoid unnecessary antibiotic exposure in all women presenting with symptoms of urinary tract infection. This requires larger epidemiological studies of women presenting with dysuria and frequency in general practice, assessing a range of clinical predictors using response to antibiotics as the primary outcome.
|
This study would not have been possible were it not for the (unpaid) efforts of the general practitioners and practice nurses of the sentinel network who identified and recruited suitable patients. Research nurses Toni Stewart, Felicity Beats, and Margaret Sutherland were responsible for the data collection. Alison Parsons provided invaluable office support for the network and follow-up of missing data. Rosemary Ikram from Medlab South and Ben Harris from Southern Community Laboratories in Christchurch facilitated smooth identification and processing of results from all specimens.
Contributors: DR and LT conceived and designed the study and interpreted the data. DR designed the protocol, coordinated the study, set up the database, participated in the data analysis and wrote the first draft of the paper with LT. SC advised on microbiological aspects of the design, planning, conduct, and analysis of the study and contributed to the writing of the paper. LF directed and carried out the statistical analysis, contributed to the writing of the paper, and took the lead in writing the sections on data analysis. DR is the guarantor.
Funding: Health Research Council of New Zealand, an independent funding body.
Competing interests: None declared
Ethics approval: Canterbury Ethics Committee.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+